Visibly reduce dark spots, age spots, and blemish marks
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist phase 2 trial in type 2 diabetes
The steady-state 24-hour urinary glucose excretion in patients with type 2 diabetes mellitus and mild, moderate, and severe renal impairment was 42%, 80%, and 90% lower, respectively, than in patients with type 2 diabetes mellitus with normal renal function
Detailed TRIUMPH-1 data is expected to be presented at the 86th American Diabetes Association Scientific Sessions later in 2026
It's often called the "healing peptide" because of its remarkable ability to support tissue repair, reduce inflammation, and accelerate your body's natural recovery processes
We provide personalized, flexible dosing options based on individual needs, designed to minimize side effects and support long-term successsomething not available with standard FDA formulations